SavedAdd your journal

Journals / Kadın Doğum Dergisi / 2006 / Cilt: 4 - Sayı: 3

The effect of postmenopausal hormone replacement therapy on depressive symptoms

Postmenopozal dönemde hormon replasman tedavisinin depresif semptomlar üzerine etkisi

İnci DAVAS
A. Ender YUMRU
Y. Tahsin AYANOĞLU
H. Erel AKSOY
Murat BOZKURT
Pages
862–865
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: HRT does not significantly improve depression parameters defined as HDS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The hypothesis is widely accepted that prevalance of psychological symptoms especially depressive disorders increases in the menopausal period.
📊
Key Findings & Data:Materials and Methods: 73 postmenopausal women of whom 33 took continue 17p-estradiol and noretisterone acetate for at least 6 months and 40 took nothing accepted into the study.
💡
Conclusion & Impact:Conclusion: HRT does not significantly improve depression parameters defined as HDS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The hypothesis is widely accepted that prevalance of psychological symptoms especially depressive disorders increases in the menopausal period. In case of emotional disorders in menopause, it's thought hormone replacement therapy (HRT) is preferred rather than psychotropic treatment. Effect of HRT was aimed on psychological condition. Materials and Methods: 73 postmenopausal women of whom 33 took continue 17p-estradiol and noretisterone acetate for at least 6 months and 40 took nothing accepted into the study. Depressive symptoms were calculated using Hamilton Depression Scale (HDS). The scores were compared on the basis of HRT usage, age, menopausal age and HRT administration methods. Results: Depressive symptoms increase but is not significant in accordance with age and menopausal age. HRT isn't cause decrease in HDS scores. There is no significant relation between HRT administration method and HDS scores. Conclusion: HRT does not significantly improve depression parameters defined as HDS.

Özet

Amaç: Menopozal dönemde ruhsal belirtilerin, özellikle de depresif bozuklukların prevalansında artış olduğu kanısı yaygındır. Menopozda duygudurum bozukluklarında psikolrop tedaviden önce hormon replasman tedavisi'nin (HRT) kullanılması düşünülmektedir. HRT'nin psikolojik duruma etkisinin ortaya koyması amaçlandı. Materyal ve Mctod: En az 6 ay süre ile kesintisiz 17(3-östradiol ve noretisteron asetat alan (n:33) ve almayan (n:40) 73 postmenopozal kadın çalışmaya alındı. Hamilton Depresyon Skalası (HDS) kullanılarak depresif semptomlar değerlendirildi. HRT kul lamını, yaş, menopoz süresi ve HRT alım yolu açısından skorlar karşılaştırıldı. Bulgular: Depresifsemptonıların, yaş ve menopoz süresi ile arttığı fakat anlamlı olmadığı, HRT'nin ise HDS skorlarını düşürmediği bulunmuştur. HRT alım yolu ile HDS skorları arasında anlamlı ilişki yoktur. Sonuç: HRT'nin HDS ile tanımlanan depresyon parametrelerinde anlamlı bir düzelme sağlamadığı görüldü.

🔖

Cite This Article

DAVAS, İ., YUMRU, A. E., AYANOĞLU, Y. T., AKSOY, H. E., BOZKURT, M. (2022). The effect of postmenopausal hormone replacement therapy on depressive symptoms. Kadın Doğum Dergisi, Cilt: 4 - Sayı: 3, 862–865. https://ajindex.com/articles/569014

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assesment, and guidelines for treatment. Harv Rev Psychiatry 1998
  2. Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynecol 1996
  3. Panay N, Studd JW. The psychotherapeutic effects of estrogens. Gynecol Endocrinol 1998
  4. Guicheney P, Leger D, Barrat J, et al. Platelet serotonin concent and plasma tryptophan in peri and postmenopausal women: variations with plasma oestrogen levels and depressive symptoms. Eur J Clin invest 1988
  5. Roca CA. Estrogen and Mood in Perimenopausal Woman. In: Mood and Psychotic Disorders in Woman. An update on treatmant Washington DC. American Psychiatric Association Annual Meeting, 1999. 6-Studd JWW, Panay N. Estrogens in the treatment of climacteric depression, premenstrual depression, postnatal depression and chronic fatigue syndrome. In: Wren BG, ed. Progress in the Management of the Menopause. Carnforth, UK. Parthenon Publishing, 1996:385-92. 7-Vliet EL, Davis VLH. New perspectives on the relationship of hormone changes to affective disorders in the perimenopause. NAACOGS Clin Issu Perinat Women's HealthNurs 1991
  6. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. ObstetGynecol 1998
  7. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998
  8. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/progestin interventions Trial. J Am Med Assoc 1996
  9. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Postmenopausal Estrogen/Progestin Interventions Trial. J Med Assoc 1995
  10. Rodriguez C, Calle EE, Patel AV, et al. Effect of body mass on the association between estrogen replacement therapy therapy and mortality among elderly US women. Am J Epidemiol 2001
  11. Henderson BE, Paganini-Hill A, Ross RK, Decreased mortality in users estrogen replacement therapy. Arch Intern Med 1991
  12. Waring SC, Rocca WA, Petersen RC, Kokemen E. Postmenopausal